SCHEMBL22929128

SCHEMBL22929128

CC(=O)C(C)CC(=O)NCCN

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
ALDH1A1 P00352 4/20 0.36
PAOX Q6QHF9 2/20 0.36
GABRR1 P24046 2/20 0.35
HPGD P15428 3/20 0.33
KMT2A Q03164 2/20 0.33
PDK2 Q15119 1/20 0.33
MEN1 O00255 1/20 0.32
CYP2C9 P11712 1/20 0.32
ALOX15 P16050 1/20 0.32
CYP2C19 P33261 1/20 0.32
HSD17B10 Q99714 1/20 0.32
GGPS1 O95749 2/20 0.32
FDPS P14324 2/20 0.32
TERT O14746 2/20 0.32
CYP1A2 P05177 1/20 0.32
TSHR P16473 1/20 0.32
NFKB1 P19838 1/20 0.32
MAOB P27338 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21888407 0.83 GABRR1 (0.50) TP53SMN1; SMN2ALDH1A1GABRR1HPGD
SCHEMBL22461923 0.83 KDM4E (0.43) TP53SMN1; SMN2ALDH1A1PAOXHPGD
SCHEMBL4505848 0.83 SMN1; SMN2 (0.52) TP53SMN1; SMN2ALDH1A1GABRR1HPGD
SCHEMBL19116288 0.82 ECE1 (0.39) TP53SMN1; SMN2ALDH1A1PAOXGABRR1
SCHEMBL20670296 0.82 TP53 (0.36) TP53SMN1; SMN2ALDH1A1PAOXGABRR1
SCHEMBL26359123 0.82 ALDH1A1 (0.39) TP53SMN1; SMN2ALDH1A1HPGDKMT2A
SCHEMBL9795280 0.81 ALDH1A1 (0.47) TP53SMN1; SMN2ALDH1A1PAOXGABRR1
SCHEMBL23585102 0.79 SMN1; SMN2 (0.41) TP53SMN1; SMN2ALDH1A1PAOXHPGD
SCHEMBL25116888 0.79 TSHR (0.45) TP53SMN1; SMN2ALDH1A1PAOXKMT2A
SCHEMBL16181344 0.79 HPGD (0.53) SMN1; SMN2ALDH1A1HPGDCYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230302091-A1 Combination Therapy with Controlled-Release CNP Agonists ASCENDIS PHARMA GROWTH DISORDERS AS (DK) 2023-09-28 US disclosed
EP-4162955-A1 CNP PRODRUGS WITH CARRIER ATTACHMENT AT THE RING MOIETY Ascendis Pharma Growth Disorders A/S (DK) 2023-04-12 EP disclosed
US-10905766-B2 Therapeutic compositions and methods for treatment of muscle wasting diseases OREGON STATE UNIVERSITY (US) 2021-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10905766-B2 Therapeutic compositions and methods for treatment of muscle wasting diseases TNNC1, PYGM, MYLK2 TP53 3633/4885SMN1; SMN2 10/4885ALDH1A1 4503/4885
US-20230302091-A1 Combination Therapy with Controlled-Release CNP Agonists CNP, NPR1, NGF TP53 4395/4885SMN1; SMN2 117/4885ALDH1A1 3630/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.